7 Questions on Managing Patients with Diabetes at High Risk of Hypoglycemia


The Endocrine Society's 2023 update to guidelines on management of patients with diabetes at high risk for hypoglycemia, the first since 2009, comes in response to a wide range of advances in the field, the authors wrote, including continuous glucose monitoring devices, algorithm-driven insulin pumps, and new glucagon formulations.

The following 7 questions on the guideline recommendations focus on characteristics of hypoglycemia; the utility of technologies to mitigate risk of hypoglycemia; and the distinctions between therapeutic agents for diabetes which can inform selection to reduce the risk for, and hasten the treatment of hypoglycemia.

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.